Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris

Main Article Content

David M Pariser
Lawrence J Green
Edward L Lain
Carsten Schmitz
Amy S Chinigo
Brian McNames
David R Berk
Jamison Hoffman
Ayman Grada

Keywords

Acne Vulgaris, Acne, Sarecycline, Safety

Abstract

Abstract not available.

References

Pariser , David M., Lawrence J. Green, Carsten Schmitz, Amy Chinigo , Brian McNamee, and David R. Berk . “Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open Label Study and a Phase I Phototoxicity Study : JCAD: The Journal of Clinical and Aesthetic Dermatology.” JCAD, November 1, 2019. http://jcadonline.com/sarecycline acne //. ClinicalTrials.gov Registration: NCT02413346


Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S. Once Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double Blind Clinical Trials. Journal of drugs in dermatology: JDD. 2018 Sep;17(9):987 96 .

Article Sidebar

Poster PDF
Published
Sep 2, 2020
DOI https://doi.org/10.25251/skin.4.supp.52

Article Details

How to Cite
Pariser, D. M., Green, L. J., Lain, E. L., Schmitz, C., Chinigo, A. S., McNames, B., Berk, D. R., Hoffman, J., & Grada, A. (2020). Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris. SKIN The Journal of Cutaneous Medicine, 4(5), s53. https://doi.org/10.25251/skin.4.supp.52
Issue
Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>